Development Stage: Preclinical stage
Indication: Solid tumors
Key Asset Highlights:
（1）Represents a novel first-in-class bispecific antibody uniquely designed for gastrointestinal solid tumors, featuring a conditional CDH17-dependent 4-1BB activation mechanism to achieve tumor-localized immune stimulation.
（2）Simultaneously targets tumor-specific CDH17 antigen and immune co-stimulatory receptor 4-1BB, restricting 4-1BB agonistic activity exclusively within CDH17-positive tumor microenvironments to avoid systemic immune overactivation.
（3）Induces robust and sustained anti-tumor immune responses by effectively activating and expanding tumor-infiltrating T cells, delivering potent tumor growth inhibition efficacy in preclinical gastrointestinal and solid tumor models.
（4）Exhibits a well-differentiated safety profile compared with conventional systemic 4-1BB agonists, eliminating off-tumor immune toxicity risks and establishing a wider therapeutic index for long-term intervention.
（5）Demonstrates reliable biochemical stability and favorable druggability in comprehensive preclinical evaluations, supporting subsequent translational research and further clinical development progression.
（6）Protected by a comprehensive global intellectual property portfolio, securing exclusive and stable worldwide development and commercialization rights for CDH17-positive solid tumor immunotherapy.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
